Cannell & Co. Petros Pharmaceuticals, Inc. Transaction History

Cannell & Co.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 07, 2021	SELL	$2.85 - $4.6 $72,629 - $117,226	-25,484 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$3.24 - $4.68 $82,568 - $119,265	25,484 New	25,484 $112,000

Ticker PTPI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 20,708,000
Market Cap $6.42M
Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for th...

Get notified when there are updates to the investment portfolio of Cannell & Co., based on Form 13F filings with the SEC.

Stay updated on Cannell & Co. with notifications on news.